Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced, that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for KYNAMRO™ (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).....
Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label homozygous familial hypercholesterolemia (HoFH). Show all posts
Showing posts with label homozygous familial hypercholesterolemia (HoFH). Show all posts
Thursday, July 19, 2012
Subscribe to:
Posts (Atom)